FDA rejects Disc’s rare disease drug despite Commissioner’s voucher

Fierce Biotech | February 13, 2026

This story zeroes in on the pathway issue, explaining that the FDA agreed the trial was adequate and well-controlled but objected to the surrogate endpoint and the lack of a sufficiently demonstrated link to clinical outcomes.